GSK1059615 is a potent, reversible, ATP-competitive, thiazolidinedione inhibitor of PI3K?? (IC50 = 2 nM).

GSK1059615 is a potent, reversible, ATP-competitive, thiazolidinedione inhibitor of PI3K?? (IC50 = 2 nM).

GSK1059615 is a potent, reversible, ATP-competitive, thiazolidinedione inhibitor of PI3K?? (IC50 = 2 nM).

GSK1059615 is a potent, reversible, ATP-competitive, thiazolidinedione inhibitor of PI3K?? (IC50 = 2 nM).

GSK1070916 is a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models.

GSK1070916 is a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models.

GSK1070916 is a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models.

GSK1070916 is a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models.

GSK1120212 (JTP-74057) strongly prevented the activities of MEK1 and MEK2 kinases rather than activities of other 98 kinases.

GSK1120212 (JTP-74057) strongly prevented the activities of MEK1 and MEK2 kinases rather than activities of other 98 kinases.

GSK1120212 (JTP-74057) strongly prevented the activities of MEK1 and MEK2 kinases rather than activities of other 98 kinases.

GSK1120212 (JTP-74057) strongly prevented the activities of MEK1 and MEK2 kinases rather than activities of other 98 kinases.

GSK126 is a potent, highly selective, S-adenosyl-methionine-competitive, small-molecule inhibitor of EZH2 methyltransferase activity, decreases global H3K27me3 levels and reactivates silenced PRC2 target genes.

GSK126 is a potent, highly selective, S-adenosyl-methionine-competitive, small-molecule inhibitor of EZH2 methyltransferase activity, decreases global H3K27me3 levels and reactivates silenced PRC2 target genes.

GSK126 is a potent, highly selective, S-adenosyl-methionine-competitive, small-molecule inhibitor of EZH2 methyltransferase activity, decreases global H3K27me3 levels and reactivates silenced PRC2 target genes.

GSK126 is a potent, highly selective, S-adenosyl-methionine-competitive, small-molecule inhibitor of EZH2 methyltransferase activity, decreases global H3K27me3 levels and reactivates silenced PRC2 target genes.

N/A

N/A

GSK-1292263 is a novel GPR119 agonist.

GSK-1292263 is a novel GPR119 agonist.

GSK-1292263 is a novel GPR119 agonist.

GSK2126458 is a highly potent, orally bioavailable inhibitor of PI3K?? and mTOR with in vivo activity in both pharmacodynamic and tumor growth efficacy models.

GSK2126458 is a highly potent, orally bioavailable inhibitor of PI3K?? and mTOR with in vivo activity in both pharmacodynamic and tumor growth efficacy models.

GSK2126458 is a highly potent, orally bioavailable inhibitor of PI3K?? and mTOR with in vivo activity in both pharmacodynamic and tumor growth efficacy models.

GSK2126458 is a highly potent, orally bioavailable inhibitor of PI3K?? and mTOR with in vivo activity in both pharmacodynamic and tumor growth efficacy models.

Akt inhibitor GSK2141795 binds to and inhibits the activity of Akt, which may result in inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis.

Akt inhibitor GSK2141795 binds to and inhibits the activity of Akt, which may result in inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis.

Akt inhibitor GSK2141795 binds to and inhibits the activity of Akt, which may result in inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis.

GSK2190915 is a potent FLAP(5-Lipoxygenase-activating protein) inhibitor with binding IC50 of 2.9 nM.